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Abstract
Primary ciliary dyskinesia (PCD) is an inherited ciliopathy leading to chronic suppurative lung disease, chronic
rhinosinusitis, middle ear disease, sub-fertility and situs abnormalities. As PCD is rare, it is important that scientists
and clinicians foster international collaborations to share expertise in order to provide the best possible diagnostic
and management strategies. ‘Better Experimental Approaches to Treat Primary Ciliary Dyskinesia’ (BEAT-PCD) is a
multidisciplinary network funded by EU COST Action (BM1407) to coordinate innovative basic science and clinical
research from across the world to drive advances in the field. The fourth and final BEAT-PCD Conference and fifth
PCD Training School were held jointly in March 2019 in Poznan, Poland. The varied program of plenaries,
workshops, break-out sessions, oral and poster presentations were aimed to enhance the knowledge and skills of
delegates, whilst also providing a collaborative platform to exchange ideas. In this final BEAT-PCD conference we
were able to build upon programmes developed throughout the lifetime of the COST Action. These proceedings
report on the conference, highlighting some of the successes of the BEAT-PCD programme.
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Introduction
Primary ciliary dyskinesia (PCD) is an inherited disorder
of motile cilia dysfunction associated with chronic sup-
purative lung disease, chronic rhino-sinusitis, middle ear
disease, situs abnormalities and sub-fertility [1]. Current
estimates suggest an incidence across Europe of 1:10,000
[2, 3], but rates as high as 1 in 400 are reported in re-
mote and consanguineous populations [4, 5]. Clinically,
impaired mucociliary clearance results in symptoms
from early life [6–8]. The burden of morbidity results
from mucous retention in the airways which leads to re-
spiratory distress in the majority of new-born infants
[6–8]; recurrent infections throughout life and ultimately
results in bronchiectasis [9, 10]; impaired lung function
[11]; and possible respiratory failure in adult life [9, 12].
Loss of cilia motility in the upper airway and eustachian
tubes can lead to middle ear disease and hearing impair-
ment, as well as problems with chronic rhino-sinusitis
[9]. Subfertility in both females and males can occur due
to motility defects in fallopian tube cilia and sperm fla-
gella [13]. During embryogenesis motile cilia drive a left-
ward fluid flow across the embryonic node that reliably
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establishes situs [14]. Patients with PCD are consequently
prone to situs abnormalities with situs inversus totalis
(SIT) in 50% and situs ambiguus (SA) in 6–12% of patients
[15, 16]. This latter group also have an increased incidence
of congenital cardiac abnormalities [15].
‘Better Experimental Approaches to Treat PCD’ [17–19]
is a collaborative initiative to drive advances in PCD re-
search, that over the last 4 years has bought together a
network of scientists, clinicians and patient groups in a
multidisciplinary network of over 250 participants from
27 countries. We have collaborated through a series of
conferences, training schools and travel bursaries to facili-
tate the wider dissemination of knowledge and research
outputs across the field of PCD. These Proceedings report
on the progress and completion of the planned deliver-
ables of BEAT-PCD which were presented during in the
4th and final meeting held in Poznan, Poland.
Jane Lucas (UK), Chair of the BEAT-PCD network,
summarised the successful completion of the objectives
that were established during the inaugural conference 4
years ago [19]. Four work groups were set up to ensure
completion of the tasks through collaboration, project de-
velopment and consensus groups. We recognised the ad-
vantages of co-hosting the conference and training school
to enhance networking between early career researchers
and seniors in the field. Dr. Lucas also discussed the suc-
cess of the Short-Term Scientific Mission (STSM) bursary
programme, through which travel between emerging and
established centres facilitated numerous successful pro-
jects and multidisciplinary collaborations.
This final conference and training school saw the con-
tributions from multiple working groups culminate in
producing consensus statements agreed across the
COST action. These focussed on the standardisation of
international reporting for Transmission Electron Mi-
croscopy (TEM) of cilia for diagnostic purposes [20] and
accuracy of immunofluorescence for PCD diagnostics
[21]. We also established clinical criteria to better recog-
nise pulmonary exacerbations in PCD [10], performed a
survey to understand variations in practice for the eradi-
cation of Pseudomonas aeruginosa [22] and defined
physiotherapy approaches to care [23].
Work group activities and training school – the
highlights of BEAT-PCD
BEAT-PCD consists of four integrated work groups:
Basic Science, Epidemiology, Clinical Care and Clinical
Trials (Fig. 1).
Fig. 1 A diagrammatic representation of the aims of work groups within BEAT-PCD and COST action-associated activities. WG = work group [19].
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Work Group (WG1) Basic Science – lead Dominic
Norris (UK): The ethos behind WG1 is ‘to get scientists
to identify what is clinically important and clinicians to
understand what is scientifically possible’. This group il-
lustrates the translation of fundamental science into
clinical research and ultimately, clinical practice. WG1
used various models, ranging from single celled to verte-
brate systems, which have led to advances in identifying
the downstream impact of specific mutations, under-
standing left-right patterning and the evaluation of PCD
specific defects. Looking to the future, WG1 is interested
in novel gene therapy approaches to rescue ciliary func-
tionality and in exploring the PCD microbiome and its
relationship with disease progression.
Work Group 2 (WG2) Epidemiology – lead Claudia
Kuehni (Switzerland): A main aim of WG2 was to im-
prove the two international collaborative PCD datasets:
the international PCD (iPCD) cohort [24] and the inter-
national PCD registry [25]. The international PCD co-
hort (iPCD) continues to expand and now includes data
from more than 3500 patients, collected from 27 centres
spanning 22 countries. Several national registries and co-
hort studies contribute the iPCD registry [26, 27]. This
has already proved to be an invaluable resource, using
existing data to review diagnostic practices, growth and
lung function in PCD, lobectomies, neonatal manifesta-
tions and will also explore genotype-phenotype associa-
tions [7, 28–33]. The international PCD registry is now
part of the ERN-LUNG network [25]. The publication of
systematic reviews and meta-analyses of published PCD
data was also a success of WG2 [9, 34]. However, this
revealed a clear need for the standardisation of clinical
outcome measures and led to the development of a com-
prehensive standardised clinical form for prospective
data collection (FOLLOW-PCD) by Myrofora Goutaki
(Switzerland) and a large multidisciplinary team of ex-
perts [35]. FOLLOW-PCD consists of 7 modules, includ-
ing a patient questionnaire on symptoms and will ensure
that future studies benefit from a consistent dataset to
robustly answer research questions [35]. Future areas of
interest for WG2 include fertility and ear, nose and
throat manifestations.
Work Group 3 (WG3) Clinical Care – lead Kim G
Nielsen (Denmark): International collaboration was a
key priority for WG3, this was successfully realised with
more than 154 multidisciplinary clinicians and patient
representatives coming together to improve PCD man-
agement. WG3 utilised surveys to consolidate knowledge
and experience from experts to successfully identify
topics and endpoints for meaningful clinical trials and
the development of a PCD-specific evidence base. The
group also focused on service delivery models, with
Bruna Rubbo undertaking semi-structured interviews
with experts across Europe, followed by the circulation
of a survey to all delegates at the 4th BEAT-PCD confer-
ence. The PCD Physiotherapy Network also aims to im-
prove standards of care, it now has 41 active
International members and serves as an excellent plat-
form to exchange ideas about service delivery and to
support peers. The development of guidelines for PCD
management through systematic review was another
WG3 priority and has led to many successful outcomes.
Suzanne Crowley et al. (Norway) published a survey on
the treatment strategies for Pseudomonas aeruginosa
eradication across 55 centres in 36 countries highlight-
ing huge variation in management and the need for
evidence-based guidelines [22]. An ongoing work group
focussed on Infection Prevention and Control plan to
produce a consensus statement in collaboration with
The PCD CORE NETWORK of the ERN-Lung and pa-
tient representatives. The TEM Expert Consensus guide-
line involved 18 centres in 14 countries through face-to-
face meetings, a Delphi consensus and exchange of sam-
ples to produce a final guideline [20].
Work Group 4 (WG4) Clinical Trials – co-led by Phi-
lipp Latzin (Switzerland) and Bruna Rubbo (UK): WG4
focussed on identifying, defining and validating outcome
measures for use in longitudinal studies. Laura Behan
(Ireland) and Jane Lucas (UK) developed and validated
the first disease-specific quality of life questionnaires
(QOL-PCD) during BESTCILIA, in collaboration with
researchers from the Genetic Disorders of Mucociliary
Clearance Consortium [36–40]. Ensuring QOL-PCD is
both valid and robust required International collabor-
ation; rigorous literature review [41]; expert and patient
interviews with psychometric analysis to ensure the clar-
ity and importance of each question. BESTCILIA and
BEAT-PCD facilitated opportunities to undertake trans-
lation of QOL-PCD into more than 8 languages [42, 43].
Siobhan Carr (UK) and Jane Lucas (UK) led the pulmon-
ary exacerbation consensus group. This group conducted
surveys at both the 2nd and 3rd BEAT-PCD meetings
followed by e-surveys to develop a definition of pulmon-
ary exacerbation. This is characterised by the presence
of three or more of the following seven items: 1) in-
creased cough, 2) change in sputum volume and/or
colour, 3) increased shortness of breath perceived by the
patient or parent, 4) decision to start or change anti-
biotic treatment because of perceived pulmonary symp-
toms, 5) malaise, tiredness, fatigue or lethargy, 6) new or
increased haemoptysis, and 7) temperature > 38 °C [10].
In Poznan, the group focussed on planning the valid-
ation of the consensus definition. The ‘Prospective ob-
servational multicentre study on variability of lung
function in stable PCD patients’ (PROVALF-PCD) (led
by Bruna Rubbo, (UK)) focussed on evaluating intra-
individual variation in lung function [44]. A total of 432
patients were recruited, providing powerful data and an
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invaluable resource for future collaborative research and
clinical care [44]. Finally, Kim G Nielsen (Denmark)
shared two draft protocols for potential randomised con-
trolled trials (RCTs) discussed in workshops held during
the 3rd BEAT-PCD Conference, including the use of
DNase and eradication strategies for early and chronic
Pseudomonas aeruginosa colonisation.
Plenaries
The success of BEAT-PCD can, in many ways, be mea-
sured by the profile of the invited speakers who were
keen to come and to deliver plenary and keynote lec-
tures. The five key-note speakers represented diverse sci-
entific and clinical research backgrounds, and delivered
their expert perspectives across a wide range of fields.
Margaret Leigh (USA) highlighted the considerable
impact of international collaborations on PCD research
throughout the history of the disease. By presenting a
timeline, she showed the first steps, from 1904 when Sie-
wert first described a case. She then discussed the strides
taken after the first national and international PCD con-
sortia were established, noting that prior to the forma-
tion of the Genetic Disorders of Mucociliary Clearance
Consortium (GDMCC) in 2004, there were 3 case re-
ports of PCD with heterotaxy. Afterwards, data from 337
PCD patients from 4 countries, on 3 continents, showed
at least a 6% incidence of heterotaxy [45]. Subsequent
studies suggest a higher incidence at 12% [16]. Gene dis-
covery has also demonstrated the power of collaboration:
the first PCD gene identified, DNAI1, was reported in a
single centre in France [46], the third gene was described
by 7 countries [47], but the ZMYND10 gene holds the
record for collaborative partnership - involving 36 insti-
tutions, 11 countries and 4 continents [48]. Professor
Leigh concluded that the future of collaboration within
PCD research looks bright with two multicenter ran-
domized control trials (RCTs) (Azithromycin [49] and
CLEAN-PCD [50]) due to report.
Marie Legendre (France) discussed the role of genetics
in PCD diagnostics. The lack of a single ‘gold standard’
diagnostic test highlights the need to combine multiple
tests to reach a definitive diagnosis [51, 52]. Whilst gen-
etic testing can confirm a diagnosis of PCD [51], it is ex-
pensive and time consuming. A confirmed genetic
diagnosis of PCD is possible in 75–80% of patients with
diagnostic test results suggestive of PCD, but is as low as
22% when based entirely on clinical symptoms. Studies
from the UK and France suggest that only 1.5% of young
adults with bronchiectasis [53] and 5.6% of patients with
recurrent airway infection [54] have a genetic diagnosis
of PCD. Hence, Marie recommended that genetic testing
should not yet be a first-tier test for PCD. The main
challenge for the geneticist is to identify bi-allelic patho-
genic PCD mutations from amongst multiple potentially
rare variants of unknown significance that are regularly
identified by next-generation sequencing. It is therefore
essential that reporting of genetic analyses includes par-
ental segregation, so that we can determine how often a
specific variant occurs in an individual with disease
within each family. Additionally, variant classification,
using the universally accepted ACMG (American Col-
lege of Medical Genetics and Genomics) guidelines, is
important as frameshift and stop mutations are easy to
classify but missense mutations can be problematic be-
cause they lead to single amino acid substitutions, with
difficult to predict effects upon the structure and func-
tion of the coded protein [55, 56]. Having a single het-
erozygous mutation in a known PCD-causative gene is
not enough to confirm the diagnosis, as the proportion
of carriers for all 40 of the known PCD genes in the gen-
eral population is approximately 10%. Examining
genotype-phenotype associations is key to determining
pathogenicity in novel gene discovery. In conclusion, at
present genotyping is not an effective screening test
when the suspicion of PCD is low and, if negative, geno-
typing does not exclude diagnosis. However, it can con-
firm diagnosis, particularly in difficult cases [57], but
results should always be interpreted in combination with
the clinical and diagnostic phenotype.
Stephanie Davis (USA) presented longitudinal data on
clinical phenotypes from several North American studies
[6, 58, 59]. The emergence of genotype-ciliary ultrastruc-
tural phenotype associations is now enabling clinical
predictions, such as mutations in certain genes not being
associated with laterality defects [15, 60]. A large cross-
sectional North American study compared lung function
in patients with different ultrastructural defects [59].
Participants with microtubular disarrangement, inner
dynein arm or central complex defects had lower forced
expiratory volume (FEV1) predicted compared to those
with isolated outer dynein arm defects or combined
outer and inner arm defects [59]. Most patients in the
group with lower lung function had CCDC39 or
CCDC40 mutations [59]. A prospective longitudinal
study demonstrated that those with CCDC39 or
CCDC40 mutations had a steeper age-associated decline
in FEV1% predicted over a 5 year follow-up period and
worse nutritional status compared to those with DNAH5
mutations [58]. A deeper understanding of genotype-
phenotype associations is essential to aid diagnosis and
prognosis of PCD. Experience strongly suggests that this
will happen most effectively through ongoing inter-
national collaboration.
Brian Mitchell (USA) explained the importance of pla-
nar cell polarity (PCP) in motile ciliated cells and how
this provides directional information allowing coordi-
nated beating of cilia to drive mucus in a particular dir-
ection. Loss of PCP in respiratory epithelial cells can
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result in PCD. He described how skin in the developing
Xenopus embryo can be used as an experimental model
to study the formation and functionality of motile cilia
[61]. He explained the power of this model system to
support the identification of novel human PCD candi-
date genes, such as GAS2L2. When GAS2L2 function is
depleted ciliary beat frequency (CBF) is not affected, but
the directionality of beating becomes disorganised - this
was observed in both the GAS2L2 depleted Xenopus em-
bryos and in the nasal epithelial cell culture of a patient
with PCD carrying GAS2L2 mutations [61]. The take
home message from this talk was that PCP is important
to MCC and that defects can lead to the clinical mani-
festations of PCD. As such, PCP of motile ciliated cells
should be considered a source for potential defects, par-
ticularly in patients without clear axonemal TEM
defects.
Pietro Cicuta (UK) reported on the development of
video analysis for cilia stroke pattern and collective wave
analysis. Differential Dynamic Microscopy allows for
quantification of CBF, metachronal wavelength and cilia
phase coherence in space and time. The technique is po-
tentially advantageous because it does not require user
input and can be used when it is not feasible to resolve
individual objects in a given field of view. Additionally,
quantitative high speed video analysis (HSVA) analysis
of the beating pattern from single cilia revealed distinct-
ive ‘fingerprints’ that can distinguish between healthy
controls and samples mutated for PCD genes, such as
HYDIN and DNAH11. Hence, the phenotypic parame-
ters demonstrated with this technique not only allow for
discrimination between healthy and PCD samples but
also between PCD genotypes [62].
Oral presentations
A wide variety of talks were given, through invitation
and abstract submission, reflecting the cross-cutting
themes that have either originated or developed through
the lifetime of the BEAT-PCD COST Action. We heard
about novel genes and gene-based therapies, ciliopathy
syndromes and fertility. These sessions ranged from fun-
damental science to clinical care, including the early re-
sults from the first multicentre clinical trial [49]. These
short presentations highlight how far the COST Action
has come in terms of research and clinical service devel-
opment across Europe through collaboration, education
and spin off research projects.
Basic sciences oral presentations
Pleasantine Mill (UK) presented data on genome editing
approaches for genome therapy in PCD. Traditional
gene therapy, or gene augmentation, can be hampered
by the large number and size of genes implicated in the
disease. CRISPR/Cas9 technology can potentially be used
to target any gene, with the possibility to repair muta-
tions via either error-free homology directed repair or
alternate homology-independent methods. Unlike ap-
proaches such as antisense oligonucleotide or mRNA-
based therapies, which require re-administration, gen-
ome editing therapies could be curative after a single ap-
plication, if done in the airway basal stem cells. The
major challenges now are to develop efficient and non-
toxic in vivo delivery systems and to better control the
editing events. Work was presented on developing new
platforms to rapidly screen for efficacy and toxicity of
both viral (lentiviral and adeno-associated viral) and
non-viral delivery routes, prior to their validation in
PCD mouse models.
Zuzanna Bukowy-Bieryllo (Poland) and Rob Hirst
(UK) both presented on the links between PCD and
ciliopathy syndromes that typically involve non-motile
cilia functions. Both groups identified mutations causing
respiratory motile cilia defects in patients with syn-
dromic features. Dr. Bukowy-Bieryllo reported X-linked
recessive hemizygous mutations and one de novo muta-
tion in the OFD1 gene, in patients with overall relatively
mild features of orofaciodigital syndrome 1 (OFDS1) ac-
companied by PCD-like respiratory symptoms (neonatal
respiratory distress, bronchiectasis, low nasal nitric oxide
(nNO)) and in one case situs inversus (SI) [63]. Pub-
lished OFD1 mutations cause a spectrum of X-linked
ciliopathies, inherited as dominant (OFDS1) or recessive
conditions (Joubert syndrome (JBTS10) and Simpson-
Golabi-Behmel syndrome 2 (SGBS2)) [64, 65]. Dr. Hirst
also reported OFD1-like patients with combined primary
cilia symptoms but PCD-typical disease features and par-
tial syndromic features. Both groups reported similar
findings of long cilia, whilst Dr Hirst presented images
of cilia with bulbous tips in both OFDS1 and Sensen-
brenner syndrome (CED)-like subjects. Some of the tips
showed apparent accumulated microtubular structures
while IFT88 protein accumulations suggested impaired
intraflagellar transport.
Selective promotion of premature termination codon
(PTC) readthrough can restore functional protein ex-
pression and improve symptoms in genetic diseases [66].
Maciej Dabrowski (Poland) presented data on
aminoglycoside-induced translational suppression of
PTC readthrough in PCD using an in vitro transcrip-
tion/translation system and an in vivo transfected epi-
thelial line [67]. In vitro results showed that the
efficiency of PTC-readthrough in human embryonic kid-
ney (HEK) cells using the dual-luciferase reporter system
was low, with read-through demonstrated in 5 of the 16
mutations analysed. Readthrough efficiency was mark-
edly lower in vivo as compared to in vitro, despite using
higher aminoglycoside concentrations. Primary cell cul-
ture of human bronchial epithelial cells from healthy
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donors was used to determine the cytotoxic effects and
ciliary toxicity of aminoglycosides, compared with non-
aminoglycosides. This demonstrated that non-
aminoglycosides (PTC-124, tylosin, amlexanox, azithro-
mycin, TC007 and escin) showed a lack of ciliotoxicity
even at high concentrations and lower cytotoxicity, in
comparison to aminoglycosides. This project was funded
the Polish National Science Centre 2016/23/N/NZ4/
03228.
Hannah Farley (UK) presented an update of her ana-
lysis of Pierce1 mice, which exhibit situs abnormalities
[68]. She followed Pierce1 gene expression with a Lac Z
reporter gene, and flow in the embryonic node using
fluorescent beads. This revealed that the gene is
expressed in the node and that nodal cilia demonstrate a
lower CBF as well as an abnormal beat pattern. TEM
analysis revealed outer dynein arm (ODA) and inner dy-
nein arm (IDA) defects in tracheal cilia of Pierce1 mu-
tants. Analysis of sperm flagella showed an increase in
static sperm and a reduced sperm count in Pierce1 mu-
tant mice, but no significant TEM defects. Together
these data make Pierce1 a candidate PCD gene.
Dorota Wloga (Poland) presented data on novel pro-
teins in cilia beat regulation using the highly ciliated
Tertrahymena (thermophila) as a model. Bioinformatic
screening was used to identify proteins conserved be-
tween humans and Tertrahymena. The CFAP43 gene
was analysed and a knockout model exhibited a 50% re-
duction in ciliary travel in comparison to wildtype (WT).
A stiff beat was evident in the CFAP43 knockout and a
similar result was seen when a partner protein, CFAP44,
was knocked out [69]. TEM analysis showed no obvious
abnormalities, but cryo-electron tomography revealed
missing tetherhead complexes in these mutants: these
structures may have a role in regulating the activity of
IDA I1α motor domains. CCDC proteins linking nexin-
dynein regulatory complex (N-DRC) and IDA g (one of
the monomeric dyneins which contribute to the molecu-
lar architecture of IDA) were also studied, with knock-
out models travelling 30% of the distance of WT cells.
This shows that whilst defects in these signal linkers be-
tween micro-complexes cannot be identified on TEM,
they appear to play a role in regulating ciliary beating.
Anu Sironen (UK) presented on PCD gene expression
in spermatogenesis. The expression of known PCD
genes was followed using RNASeq both during mouse
spermatogenesis and in human testis [70–72]. Immuno-
fluorescence analysis was conducted for human sperm
using antibodies that detect known PCD gene products.
Relatively high expression in male germ cells as well as
mutations known to cause male infertility were reported
for the PCD-associated dynein preassembly genes. How-
ever, there were differences in expression of axonemal
structural components noted between testis, sperm and
cilia. Radial spoke head 4 (RSPH4) expression was very
low in the testis and no protein localization was identi-
fied in sperm. However, RSPH 1, 3 and 9 were expressed
in the testis and sperm motility defects have been ob-
served. In addition, there appear to be expression differ-
ences for axonemal dynein heavy chains in cilia versus
sperm. Surprisingly, DNAH11 and DNAH5 exhibited
very low expression in the testis, consistent with them
being dispensable in sperm, while DNAH8 expression
was high in testis. Gene expression levels can be used to
increase understanding of the relative importance of
proteins in specific tissues. A greater understanding of
PCD patient sperm development may shed a light on the
role of these proteins in motile cilia.
Isabella Aprea (Germany) presented a comparative
study comparing the dynein pre-assembly machinery in
respiratory cilia and sperm flagella. Respiratory cilia and
sperm flagella from six PCD patients with known ODA
and IDA defects were analyzed using fluorescent anti-
bodies to ciliary proteins and TEM. Sperm cells and re-
spiratory cilia of most affected individuals presented
with a loss of ODA and IDA components, including
DNAI1, DNAI2 and DNALI1. Moreover, TEM confirmed
the ODA defect. In DNAAF2 individuals, analysis of the
cilia revealed absence of ODA components only in the
distal axonemes, whilst sperm cells showed a loss of
ODA along their entire length. The similarity of results
seen in respiratory cilia and sperm cells suggest that the
processes governing dynein preassembly are conserved
in both cell types.
Paweł Niewiadomski (Poland) used RNAi-based loss-
of-function studies coupled with immunofluorescence
microscopy and semi-automated image processing to
identify novel players in the ciliary transport machinery
of mammalian cells. Co-immunoprecipitation and im-
munoblotting were used to dissect potential interactions.
Results showed that a macromolecular complex not pre-
viously implicated in soluble protein transport interacts
with soluble Gli transcription factors and is critical for
their delivery to the primary cilium. The Gli proteins are
the key effectors of hedgehog (hh) signalling and need to
be shuttled into and out of cilia for hh signalling to func-
tion normally. Further, Paweł showed that Gli proteins
interact with the exocyst complex and that inhibition of
exocyst function blocks Gli accumulation in cilia. Paweł
suggested a possible mechanism could be that the exo-
cyst forms a scaffold for the transport of Gli proteins to
the cilium base via cilium-bound vesicles.
Clinical oral presentations
Bernard Maître (France) shared findings from a study
using an automated computed tomographic (CT) scor-
ing system to objectively quantify lung disease in adults
with PCD [73]. This aimed to develop an automated
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algorithm that can generate a score for severity of PCD
lung disease in adults. Sixty-two adult patients with PCD
and available CT scans were retrospectively included.
The clinical characteristics of the group included a mean
FEV1 of 67% and almost one third of participants having
had a previous lobectomy. The CTs were then reviewed
using the algorithm and compared with visual CT scores
(generated by trained radiologists) and spirometry re-
sults for each patient. CT-density scores showed moder-
ate to good negative correlations with FEV1 and FVC
with fixed thresholds, however even stronger negative
correlations were observed when thresholds were ad-
justed for mean lung density + 1 standard deviation. In
summary, generating and using an automated CT score
is feasible for adult patients with PCD [73]. This score
can be used in non-standardised CT examinations and
correlates with spirometry parameters. However, limita-
tions include: the algorithm misreading blood vessels as
‘lung abnormalities’ and failing to identify air trapping as
abnormal. Maître and colleagues are hoping to use the
score as an objective outcome parameter in a clinical
and research context.
Bruna Rubbo (UK) presented on the accuracy of high-
speed video analysis (HSVA) to diagnose PCD [74, 75].
Three scientists analysed 120 movies of cilia, having
been blinded to the diagnosis and other test results. A
random sampling of patients from multi-disciplinary
team (MDT) outcomes were selected (50% PCD, 30%
highly unlikely, 20% inconclusive). Results for PCD diag-
nosis were stratified by comparing outputs from scien-
tists to the standards described in the ERS diagnostic
guidelines [76] (100% sensitivity and 96.2% specificity)
and MDT outputs (96.7% sensitivity and 91.1% specifi-
city). All three scientists agreed with each other for the
PCD positive cases, whilst less agreement was seen in
cases with inconclusive findings according to the MDT
and the ERS diagnostic guidelines. Re-analyses of a ran-
dom sample of 20 videos a year after the study was con-
ducted revealed good intra-observer agreement.
Following this study, the archived video library can now
be accessed within the UK training centres for HSVA
training purposes.
Nisreen Rumman (Palestine) shared her experience of
setting up a PCD service in Palestine. Nisreen received
support from the COST Action, ERS and Circassia to
visit Southampton and University College London in the
United Kingdom. At present, clinic resources are limited
and only patients with a high suspicion of PCD (high
PICADAR score [8] or low nNO) receive diagnostic test-
ing – this is achieved in collaboration with TEM services
in Southampton and genetic analyses at University Col-
lege London Great Ormond Street Institute of Child
Health. Of 142 samples sent for TEM, 38 were abnor-
mal, and in the majority, a genetic mutation was
identified. Six patients with normal TEM showed genetic
abnormalities (five with DNAH11 and one with HYDIN
mutations). The majority had consanguineous parents
(88%); two thirds had neonatal respiratory distress syn-
drome (NRDS). Situs inversus was present in 54, 11%
have congenital heart disease, 2% had undergone previ-
ous lobectomy. Screening relatives of these index pa-
tients allowed for identification of another 25 individuals
with PCD. This highlights that a functioning diagnostic
service can be set up in less than 4 years through Inter-
national collaboration. There are ongoing plans to estab-
lish HSVA, TEM, IF and genetic testing locally in
Palestine in the near future.
Ewa Zietkiewicz (Poland) reported epidemiological
data on the genetic basis of PCD in Poland, including
the frequency of genetic profiles and detection efficiency
in the Polish population. Situs abnormalities were
present in 40% of cases identified from the PCD refer-
ence centre at Rabka but less than 25% from other Pol-
ish centres. All the patients included in this study
underwent genetic screening for PCD mutations, regard-
less of supporting diagnostic data, including a panel of
21 PCD genes and whole exome sequencing in 120 pa-
tients. Unsurprisingly, access to diagnostic tests is easier
in the reference centre (90% of diagnoses from Rabka
were supported by at least one of nasal nitric oxide
(NNO), TEM or HSVA), whilst in the other health cen-
tres these investigations were performed in only one
third of cases. One hundred thirty-four pathogenic mu-
tations have been detected in the population to date.
One hundred and two of these mutations were specific
to either individuals or families (and therefore individual
mutations occurred at low frequency). However, of the
recurring mutations, there appeared to be a potentially
‘Polish-specific’ profile. The most frequent pathogenic
variant was SPAG1 (exon 16), which has previously been
described in patients of Northern European ancestry
[77]. There was also a relatively low contribution from
DNAH5 sites when compared with other populations
[78]. Mutations were identified in 65% of the cohort but
Ewa speculated that reduced access to diagnostic PCD
tests in the local health centres may have led to over-
diagnosis in some cases, and therefore a reduction in
gene detection rates.
Myrofora Goutaki (Switzerland) presented data on the
prevalence of neonatal manifestations in PCD from 13
datasets of the iPCD multinational cohort [7, 24], with
almost complete datasets for the neonatal period. One
thousand one hundred and seventy-five patients had in-
formation on NRDS and 1053 had information on any
neonatal manifestation. The prevalence of NRDS was
40% and of any neonatal manifestation (including rhin-
itis, cough, oxygen or ventilation requirement, hydro-
cephalus or admission to neonatal intensive care) was
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66%. After adjusting for sex and laterality, mean age of
diagnosis was lower in patients who reported neonatal
symptoms (12 versus 14 years, p < 0.001). Increased
awareness and close collaboration with neonatologists is
needed to diagnose PCD earlier in these patients.
ERN-lung PCD core and COST action 2
The EU funded European Reference Network (ERN)
project is a patient-centric, international scientific and
clinical network committed to the development of
knowledge bases for rare and complex disease. There are
currently 23 ERNs in place and Heymut Omran
(Germany) delivered a presentation on the benefits of
being part of the PCD-CORE in ERN-Lung. Health care
centres must meet a set of minimal requirements to
apply for full or supporting membership in the PCD
CORE, including a minimum number or patients served
by the centre and access to central diagnostic tests.
As the BEAT-PCD Cost Action comes to a close, we
looked to the future with discussions of the next steps for
this thriving research community. We are dedicated to
continuing the exceptional work of BEAT-PCD with an
application for a collaborative Cost Action 2 called Preci-
sion Medicine for Motile Ciliopathies (PreMedCILIA).
This will aim to center around the translation of motile
ciliopathy research into individualised care and thera-
peutic approaches for our patients, with the intention of
attracting input from the pharmaceutical industry.
Revisiting BESTCILIA: the azithromycin study
BESTCILIA was a research programme funded by the
European Commission 7th Framework Programme
which preceded BEAT-PCD. The initial results of the
highly anticipated phase III RCT of azithromycin main-
tenance therapy were presented by Helene Kobbernagel
and Kim G Nielsen. This double-blind, parallel group
study is the first multinational pharmacotherapy RCT in
PCD and it aimed to examine the efficacy and safety of
azithromycin maintenance therapy for 6 months, com-
pared to placebo [49]. Despite being slightly underpow-
ered for the primary outcome, the results were
promising regarding exacerbations. At the time of the
conference further analyses were ongoing and publica-
tion was pending. The study, together with the previous
trial on hypertonic saline, again highlights that recruit-
ment is challenging in this rare disease and therefore a
multinational collaborative approach is required [79, 80].
PCD training school highlights
Claire Hogg (UK), PCD Training School Lead, discussed
the evolution of the training school which first met in
Bern, Switzerland in 2015 with approximately 30 dele-
gates. Since then it has merged with the BEAT-PCD
conference and grown with a powerful momentum. Over
the years it has facilitated the career development of
early career researchers through an important number
of short-term scientific missions (STSMs) [28]. The bur-
sary scheme which facilitates travel to-and-from special-
ist PCD centres has increased cross-site collaborations,
advanced diagnostic applications and resulted in the cre-
ation of new diagnostic centres across the world. Some
STSMs were given to senior scientists to transfer know-
ledge and experience but the majority were given to
early career researchers who travelled to learn new tech-
niques for a wide range of applications (diagnostic, clin-
ical and research). Twenty-nine STSMs have taken place
throughout BEAT-PCD, 11 of which occurred in year 4,
including destinations such as Tubingen, Lisbon,
Palestine and the UK. Many of these were presented in
the BEAT-PCD poster session detailed in Table 1. In
summary, the training school, its meetings and STSMs
have contributed towards the training of a new gener-
ation of scientists from multiple fields involved in PCD
research who will ultimately be responsible to take this
consortium forward.
Training school workshops
Using the standardised PCD clinical follow-up form
(FOLLOW-PCD) for and QOL-PCD in clinical care and
research
Laura Behan (UK) and Myrofora Goutaki (Switzerland)
led this workshop with the aim of familiarising the dele-
gates with these two instruments of data collection. They
revisited the development, validation and translation of
these tools into clinical practice and reviewed available
versions that can be accessed for patients. Laura Behan
demonstrated how to deliver and score the QOL-PCD
questionnaire during an interactive session [36–38, 40].
Myrofora Goutaki showed how to navigate FOLLOW-
PCD with hands-on experience of entering patient data
and extracting their datasets [35]. This workshop gave
an insight into how these tools can be used in research
and clinical practice.
Nasal NO in infants
Eric Haarman (Netherlands) and June Marthin
(Denmark) led this session which highlighted the im-
portance of early PCD diagnosis and the diagnostic value
of nNO in infants. Use of nNO as a diagnostic test is
well established in school age children and adults [52,
81–85]. It is important to understand the factors which
influence the interpretation of nNO in infancy. Nasal
NO is initially extremely low in healthy infants but in-
creases considerably in the first few months of life [86–
88]. It has also been shown that transient reductions in
nNO (even below the expected cut-offs for PCD) can
occur during to respiratory tract infections in infants
[86]. It was therefore suggested that age-standardised
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Table 1 A summary of the posters presented at the 4th BEAT-PCD Conference, including poster titles and authors
Poster Title Authors (Country of first author)
A review of the care of children and young people with Primary Ciliary
Dyskinesia (PCD) in a specialist PCD service in England
Wilkins H, Harris A, Baynton L, Bright V, O’Callaghan C, Carr S, Chetcuti P,
Copeland F, Driessens C, Friend A, Hogg C, Kang R, Kenia P, Kewell C,
Lucas J, Marsh G, Moya E, Narayanan M, Packham S, Parsons A, Rubbo B,
Truscott A, Waller K, Walker W (United Kingdom)
The International PCD Physio Network Schofield LM, Bright V, Kang R, Marsh G, Wilkins H (United Kingdom)
Prescription patterns of inhaled corticosteroids in children with primary
ciliary dyskinesia in Austria and the UK: a 2-center comparison
Gaupmann R, Cobb K, Richardson C, Marsh G, Lee K, Jamalzedeh A, Bush
A, Hogg C, Carr S, Dehlink E (Austria)
Doctors’ treatment recommendations for Swiss patients with Primary
Ciliary Dyskinesia: a retrospective cohort study
Wisse A, Goutaki M, Halbeisen FS, Barben J, Casaulta C, Clarenback C, Jung
A, Latzin P, Lazor R, Lin D, Lurà M, Rochat I, Kuehni CE (Switzerland)
The Swiss Primary Ciliary Dyskinesia Registry (CH-PCD): an update Goutaki M, Halbeisen FS, Wisse A, Barben J, Casaulta C, Clarenback C, Jung
A, Latzin P, Lazor R, Lin D, Lurà M, Rochat I, Tschanz SA, Maurer E, Kuehni
CE (Switzerland)
Clinical outcome measures for use in primary ciliary dyskinesia: a scoping
systematic review
Rubbo B, Gahleitner F, Jackson CL, Goutaki M, Halbeisen F, Hueppe JF,
Behan L, Thouvenin G, Kuehni C, Latzin P, Lucas J (United Kingdom)
Validation of paediatric health-related quality of life instruments for pri-
mary ciliary dyskinesia
Behan L, Leigh M, Dell S, Quittner A, Lucas J (United Kingdom)
Development and psychometric validation of the Greek version of the
adult QOL-PCD questionnaire: preliminary results
Ioannou P, Kouis P, Middleton N, Kakkoura M, Kaliva M, Toliopoulou A,
Behan L, Lucas J, Yiallouros P (Cyprus)
Early Lung Disease: Multiple Breath Washout to assess Lung Clearance
Index in preschool and school children with PCD in comparison to CF
and healthy controls
Roehmel JF, Doerfler F, Staab D, Mall M (Germany)
Increased resting energy expenditure in children with Primary Ciliary
Dyskinesia
Ullmann N, Diamanti A, Lo Scalzo L, Cremisini Carosi F, Pizziconi C, Cutrera
R (Italy)
Lung Structure and Function in PCD – how to best monitor disease
progression?
Rodrigues T, Lopes C, Bárbara C (Portugal)
Developmental and behavioural problems in preschool-aged primary cil-
iary dyskinesia patients
Zengin Akkus P, Gharibzadeh Hizal M, Ilter Bahadur E, Ozmert E, Eryilmaz
Polat S, Ozdemir G, Karahan S, Yalcin E, Dogru Ersöz D, Kiper N, Ozcelik U
(Turkey)
3D printed models as an educational tool depicting ciliary changes in
Primary Ciliary Dyskinesia (PCD)
Thompson J, Jackson C, Doherty R, Lucas J (United Kingdom)
STSM: Diagnosis of Primary Ciliary Dyskinesia using advanced techniques:
High Resolution Tomography
Pinto A, Daudvohra F, Shoemark A, Rasteiro M, Lopes S (Portugal)
Whole exome sequencing reveals novel mutations in Turkish siblings
with PCD
Arik Sever E, Karadag B, Sezerman OU (Turkey)
Increasing the diagnostic yield of whole exome sequencing in primary
ciliary dyskinesia through targeted copy number analysis
Bell BST, Pengelly RJ, Collins AR (United Kingdom)
Genetic characterisation of Spanish patients with Primary Ciliary
Dyskinesia
Camats-Tarruella N, Fernández-Cancio M, Baz-Redón N, Rovira-Amigo S,
Garrido-Pontnou M, Antolin M, Ruela A, Armengot-Carceller M, Escribano
A, Dasi F, Moreno-Galdó (Spain)
Do mutations in LRRC56 cause human motile ciliopathies? Hirst R, Watson C, Rutman A, Williams G, Chetciti P, Sheridan E,
O’Callaghan C (United Kingdom)
Characterisation of a new CCDC40 zebrafish mutant line generated by
CRISPR-Cas9
Rasteiro M, Pinto A, Lopes S (Portugal)
Preliminary results of high-speed video-microscopy and immunofluores-
cence analysis in a Spanish cohort of patients with primary ciliary
dyskinesia
Baz- Redón N, Rovira-Amigo S, Camats-Tarruella N, Fernández-Cancio M,
Garrido-Pontnou M, Antolin M, Ruela A, Escribano A, Dasi F, Armengot-
Carveller M, Moreno-Galdó A (Spain)
iPSCs-derived airway epithelium for primary ciliary dyskinesia modeling
and investigation of personalized medicine
Mianné J, Ahmed E, Bourguignon C, Fieldes M, Vachier I, Bourdin A, Assou
S, De Vos J (France)
Oxidative profile characterisation in nasal epithelial cells of PCD patients.
Development of a new diagnostic algorithm
Ruela A, Castillo S, Herrera G, Escribano A, Armengot M, Dasi F (Spain)
STSM in Lisbon: Analysis of the cilia-related phenotypes in CFAP300-
knockdown zebrafish
Rabiasz A, Rasteiro M, Lopes S, Witt M, Zietkiewicz E (Poland)
STSM in Tübingen: Training in small-scale quantitative proteomics of cil-
iary proteins
Bukowy-Bieryllo Z, Beyer T, Boldt K, Ueffing M, Witt M, Zietkiewicz E
(Poland)
Poster titles presented by authors (country of first author) at the 4th BEAT-PCD Conference
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nNO normative values are urgently needed for healthy
and PCD infants, with regulation of measuring tech-
niques for this group. Particular focus was given to the
findings of the recent proof of concept study which
demonstrated the feasibility of different methods to
measure nNO in infants [89]. Three suggested methods
include: the conventional method of tidal breathing for
30 s, measuring 3 peaks; tidal breathing for 4 s, measur-
ing 1 peak and vacuum sampling using the pinch
manoeuvre over 1–2 s. The workshop included an inter-
active session demonstrating the NIOX VERO machine
and a presentation of practical techniques to improve
tolerance of the technique in the infant group. The
workshop generated discussions regarding a possible
multicentre study to determine the discriminative ability
of nNO in infants.
Systematically analysing genotype-phenotype association in
mouse: mining international mouse phenotype consortium
(IMPC) data
Dominic Norris (UK), Ruairidh King (UK) and Daniel
Delbarre (UK) led this workshop introducing the IMPC,
which is generating broad spectrum multi-dimensional
phenotyping data for null alleles of every protein-coding
gene in the mouse. This provides novel candidate genes
for any given disease and provides phenotypic data for
characterised and uncharacterised genes. The workshop
highlighted the PCD-relevant phenotyping tests available
and included an interactive session on how to access
freely available data and navigate the IMPC portal. This
provided delegates with the necessary skills to search for
information on the genes or phenotypes of interest
which can then be utilised to inform future studies.
Nasal NO in the diagnostic workup of PCD: clinical
decisions and hands-on workshop
Jane Lucas (UK), Claudia Kuehni (Switzerland), Amanda
Harris (UK) and Bruna Rubbo (UK) discussed the rec-
ommendations from the ERS guidelines for diagnosis of
PCD [51, 76], which include that nNO should be used in
the diagnostic work-up of patients 6 years and older
using a chemiluminescence analyser with velum closure;
those under 6 years should attempt nNO with tidal
breathing; and that if there is a strong clinical history to
support diagnosis, further investigations should be pur-
sued even if nNO is normal. The workshop concluded
with an interactive session learning to use the NIOX
VERO machine.
Imaging modalities in PCD – recent research advances and
the role of new techniques in clinical practice
Tom Semple (UK) began by demonstrating the appear-
ances of abnormal situs (inversus and heterotaxy syn-
dromes) on x-ray and CT, followed by an interactive
session examining various clinical cases. Tom then dis-
cussed structural magnetic resonance imaging (MRI)
and outlined the fundamental strengths and weaknesses
of CT vs MRI. He discussed methods for deriving quan-
titative measures of disease severity from each modality
and their limitations. The use of visual scoring systems
in current clinical imaging practice has disadvantages,
including the significant inter-reader variability, time re-
quired for scoring and specialist training. New respira-
tory applications of MRI and CT were discussed
including quantitative CT and ventilation-perfusion MRI
with preliminary data from Fourier decomposition
ventilation-perfusion MRI, oxygen enhanced MRI and
the application of deep learning imaging research.
Immunofluorescence microscopy as a diagnostic tool for
PCD
The workshop started with a brief introduction about
what an antibody is, types of hosts and differences be-
tween monoclonal and polyclonal antibodies. Niki
Tomas Loges (Germany) then explained the basis of im-
munofluorescence. The University of Münster immuno-
fluorescence protocol was reviewed as an example,
including fixation; permeabilisation; blocking; incubation
with the primary antibody and incubation with the sec-
ondary antibody. Niki also showed examples of different
antibodies that are available to detect defects of ODA-
and IDA- complexes, the radial spoke, the Nexin-Dynein
regulatory complex and microtubule disorganisation de-
fects. The workshop discussed trouble shooting for com-
mon technical difficulties and quality control of primary
and secondary antibodies.
Physiotherapy – airways clearance –quality as well as
quantity!
Gemma Marsh (UK), Lynne Schofield (UK) and Hannah
Wilkins (UK) led an interactive problem-based session
which examined the various physiotherapy techniques to
manage the upper and lower airways in PCD [23, 90].
This involved a presentation by a local patient who
shared his experience of daily physiotherapy, demon-
strated his routine and explained its impact on his life.
The roles of exercise, posture and continence were ex-
plored. The delegates split into smaller breakout groups
to discuss specific cases and this also provided an inter-
active platform to share and explore their own challen-
ging cases.
How do the cilia in a cell co-ordinate their motion – what
we know and what is left to understand
This workshop, facilitated by Pietro Cicuta (UK) and
Dominic Norris (UK), addressed how cilia are coordi-
nated, both from experimental and conceptual methodo-
logical approaches. This was achieved using a ‘question
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and answer’ session. Pietro discussed the air-liquid inter-
face (ALI) epithelial cell model he currently utilises to
assess the co-ordination of ciliary beating [91]. This
method enables longitudinal visualisation of the cells as
they proliferate and expand on the transwell membranes.
When flow is added to growing cells at the ALI, the cilia
align; even when flow is subsequently removed the cilia
on these cells remain aligned. However, flow does not
cause cilia to align if applied only once the cells are fully
differentiated, indicating that there is a window of time
when this is possible. Adding artificial flow provides a
modality for representing respiratory flow in vitro. There
was active discussion and interaction during the session.
However, the question of what enables the ‘healthy’ co-
ordination of cilia in tissues is still far from understood.
Applying for ERS fellowships: how to increase your chances
Claudia Kuehni (Switzerland) and Myrofora Goutaki
(Switzerland) summarised a wide range of ERS fellow-
ship opportunities, including practical information such
as the person specification for each fellowship and the
timelines for application [92]. Opportunities are: the
short and long-term research fellowships (ranging from
3 to 12months in duration), the Marie Curie/Respire −
36months long), clinical training fellowships to develop
specific skills, guideline methodology with Cochrane
based in Spain or NICE based in the UK and also public
health fellowships which give practical experience on
population-based research. Claudia and Myrofora gave
feedback based on personal experience from the per-
spective of both the evaluator and applicant. This was
followed by an interactive question and answer session.
How to establish and develop a PCD diagnostic facility
Claire Hogg (UK), Jane Lucas (UK), Andreia Pinto
(Portugal) and Nisreen Rumman (Palestine) started the
session by providing an overview of the PCD diagnostic
tests including the standards discussed in the ERS diag-
nostic guideline [51, 76, 93]. They also shared their own
experiences of setting up and maintaining a diagnostic
service in different environments – including examples
of how the EU PCD Consortia of BEAT-PCD, BESTCI-
LIA and the PCD Taskforces have allowed the collabor-
ation, mentorship and support necessary to develop the
required skill sets across Europe and other nations
around the world. They discussed the minimum require-
ments in PCD testing to secure a diagnosis and how to
access training and support to develop specific services,
with particular reference to contacting experts through
the PCD Reference Centre Network established with the
ERN-Lung programme. Nisreen Rumman discussed the
approaches and challenges of setting up a new diagnostic
service in Palestine [81] and Andreia Pinto presented
her experiences from Portugal.
Consensus statement workgroups
Developing a validation study for the definition of
pulmonary exacerbations
This workshop led by Claudia Kuehni (Switzerland) and
Siobhán Carr (UK) was attended by delegates from var-
ied clinical backgrounds. The aims were to review the
development of the 2018 Expert Definition of Pulmonary
Exacerbations in Clinical Trials Consensus and to ex-
plore the options for a future validation study and dis-
cuss different approaches [10].
It was discussed that the optimal approach would be a
prospective multi-centre study capturing detailed stan-
dardised information on all items used to define an ex-
acerbation, such as patient reported symptoms,
measured traits (such as temperature) and investigations.
Ideally it should include not only the items that were fi-
nally included in the definition, but also those that were
discussed but discarded. In the interim, the first step
agreed was to analyse the datasets recorded in the Azi-
thromycin RCT [49] and PROVALF-PCD [44]. Most
items used for defining an exacerbation had been
assessed in these studies, although not exactly in the
same manner. It was also agreed that the items used to
define an exacerbation should be used in all clinical
studies on PCD in the future.
International consensus group for immunofluorescence
microscopy to diagnose PCD
Heymut Omran (Germany) chaired a discussion on the
need to establish a consensus guideline for the use and
reporting of immunofluorescence in diagnostic PCD
testing. Discussions focussed on practical techniques
which are largely protocol driven and vary between cen-
tres (including sample collection, solutions for suspen-
sions, storage methods and slide types). Particular focus
was given to the importance of quality control. The po-
tential to collaboratively compare test results between la-
boratories using a ring trial was discussed. Developing
standards for immunofluorescence reporting was also
discussed, including comments regarding the quality of
samples. An email list was generated and circulated
amongst attendees with the intention of establishing an
immunofluorescence network.
Poster session
The BEAT-PCD Conference and Training school in-
cluded a poster session. Titles and authors are sum-
marised in Table 1.
Case Presentations
Difficult diagnostic cases
The diagnosis of PCD remains complex, even with the
publication of evidence-based guidelines as there are still
many subtle cases were investigations remain
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inconclusive [1, 76, 94]. For this reason, the BEAT-PCD
Conference and Training School included an open
forum to review difficult diagnostic cases across centres.
Suzanne Crowley (Norway) presented a term infant
with neonatal pneumonia and persistent wet cough, es-
pecially related to feeds. He was initially thought to have
unsafe swallow with possible aspiration but later showed
more typical features of PCD with upper and lower air-
way disease. Investigations were unusual, revealing a
nNO of 50 ppb, sparse and short cilia on several brush-
ings and it was unclear if these were primary or second-
ary abnormalities. Genetic testing was negative for genes
associated with reduced generation of motile cilia (in-
cluding CCNO and MCIDAS [95]) but showed two vari-
ants in DNAH9. Defects in this gene were reported to
cause absent ODA in the distal part of the cilium [96].
The patient’s immunofluorescence showed that DNAH9
was not absent but mislocalised and that there was a
lack of cilia. Further diagnostic steps were discussed, in-
cluding ALI culture to assess ciliogenesis and testing the
DNAH9 variants at the RNA level in the nasal brushing,
or even whole exome/genome sequencing to look for an-
other causative gene.
Sandra Rovira (Spain) presented a 48-year-old patient
with recurrent upper airway symptoms, SIT, chronic si-
nusitis and recurrent suppurative OM since childhood.
There was no significant lower airway disease. Investiga-
tions for cystic fibrosis, immunodeficiency and allergies
were negative. PCD diagnostics showed normal nNO
(986 ppb), normal CBF but areas of stiff dyskinetic cilia,
and pathogenic genetic variants. Interestingly, immuno-
fluorescence showed unusual staining for DNAH5 with
more intense fluorescence in the proximal axoneme. As-
sembled experts commented that these appearances
have been observed by others but that they normalised
upon repeat testing or ALI culture. There was agree-
ment about the value of genetic testing in difficult diag-
nostic cases.
Lynne Schofield (UK) presented a Pakistani family
with 3 siblings who had wet cough, chest infections, rhi-
norrhoea and hearing deficits, without laterality defects
or bronchiectasis. Their mother also had wet cough with
rhinorrhoea. Nasal NO was 160 ppb and 3 ppb for the
two siblings who were able to perform the test. Other
PCD diagnostics showed heavy mucous impedance, dys-
kinetic cilia with a staggered or double beat and with
tips bent at 90 degrees, but CBF and TEM were normal.
Immunofluorescence and ALI cultures were unsuccess-
ful, and genetic testing varied between individuals within
the family. In discussion it was raised whether this fam-
ily truly has PCD or another muco-ciliary clearance ab-
normality. The group agreed that PCD diagnosis cannot
be confirmed without TEM or genetics, but patients
should be managed as PCD until proven otherwise. It
was also discussed that the characteristic double beat
which has been seen in other cases of PCD, is a strong
indicator that further testing is required to confirm or
exclude a diagnosis.
Laura Gardner (UK) presented a 6-month-old boy
with levocardia, abdominal SI, left atrial isomerism and
functional hyposplenia. He had no respiratory symp-
toms but developed neonatal seizures which were likely
secondary to cerebral infection. This warranted genetic
testing through the Next Generation Children Project
[97], which revealed 2 mutations in DNAH11 (one
pathogenic and another missense variant of unknown
significance). Despite an absence of symptoms, PCD
diagnostics were pursued and showed subtle stiff cilia
on HSVA but normal TEM and immunofluorescence.
Given that around 30% of patients with PCD have ap-
parently normal ciliary ultrastructure on TEM [98], in-
cluding associated with DNAH11 mutations, 3D
electron tomography was pursued. Findings were con-
sistent with a DNAH11 genetic defect, with an ODA to
microtubular doublet volume ratio of 10.24%. This is in
keeping with published data showing a median ODA to
microtubular doublet volume of 10.3% (interquartile
range 9.3–10.5%) in DNAH11 subjects, compared to
13.8% (12.9–14.4%) in controls [98]. It is therefore likely
that DNAH11 c10472G > A; p.(Arg3491His) is a novel
pathogenic mutation associated with PCD. However, it
was questioned whether this patient can be labelled as
PCD given his relative lack of respiratory symptoms.
The group agreed that clinical follow-up is warranted as
PCD has a spectrum of clinical severity across known
structural and genetic mutations.
Randy Suryadinata (Australia) presented a 2.5-year-old
boy with chronic cough, recurrent otitis media and per-
sistent nasal discharge. There was no neonatal respira-
tory distress or laterality defects. Genetic testing
revealed two heterozygous mutations in HYDIN in cis
(which were shared with the unaffected mother and sis-
ter), and an additional mutation in DNAH11. HSVA
showed reduced beat amplitude and circling movements.
TEM was unremarkable, but tomography exposed a pos-
sible volume loss of the HYDIN projection, described as
a ‘missing bridge’. The questions raised with this case
were whether a digenic inheritance pattern involving 2
combined mutations (HYDIN and DNAH11) can cause
PCD, or whether the specific HYDIN mutations could
cause a dominant form of PCD. It was noted that
HYDIN mutations can be difficult to define, due to the
HYDIN2 copy gene, as well as it being large gene with
multiple polymorphisms. It was thought that a dominant
inheritance was unlikely. Segregation studies, testing the
mother and sister who share the mutations, were sug-
gested. Linkage studies by haplotype testing may also be
informative.
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Nagehan Emiralioglu (Turkey) presented two cases. A
3-year-old boy with failure to thrive, developmental
delay, polyuria and polydipsia. He was born at term to
consanguineous parents without neonatal complications.
Investigations revealed features of Fanconi Bickel syn-
drome which was confirmed by genetic testing (SLC2A2
gene). At age 4, he presented to respiratory services with
chest infections, persistent wet cough, recurrent rhinosi-
nusitis, and SIT. HSVA on cell culture revealed dyski-
netic cilia, TEM is still pending. Genetic experts at the
meeting discussed potential for a modifier gene effect,
especially since the gene for Fanconi Bickel syndrome
maps to chromosome 3q26.1-q26.3, and CCDC39 to
chromosome 3q26.33.13. The group commented that
“contiguous gene deletion syndrome” can be another
possible reason for this, as described with DNAH5 and
cri du chat syndrome [99]. It is therefore warranted in
this case to check if CCDC39 is absent by immunofluor-
escence, and also perform karyotyping to check for dele-
tions. In the second case, a 4-month-old infant, born at
term to consanguineous parents with neonatal respira-
tory distress, SIT and skeletal dysplasia, to consanguin-
eous parents. He presented to respiratory services with
recurrent wheezing, pneumonia and persistent nasal dis-
charge. His mother has bronchiectasis and history of
lobectomy, two uncles and grandfather also have bron-
chiectasis. HSVA for both the infant and mother re-
vealed almost static cilia. The question was raised about
the genetic causes of skeletal dysplasia as part of a pri-
mary ciliopathy with a respiratory phenotype. The group
commented that there is increasing reports of primary
ciliopathies having motile ciliary defects as well [100]. It
was noted that in fish models if you knock out any PCD
gene, the fish develops scoliosis [101]. Some have ob-
served scoliosis in PCD patients but whether there is a
link between remains unknown.
Difficult management cases
The limited evidence-base for best clinical practice in
PCD means that management can be challenging for in-
dividual clinicians, even in larger centres [1, 102].
BEAT-PCD included an interactive session to discuss
difficult cases with the hope of consolidating collective
experiences and developing an expert consensus.
Vendula Martinu (Czech Republic) presented the case
of a 13-year-old girl with PCD (DNAH5, ODA defect),
recurrent pulmonary exacerbations and faltering growth.
Bronchoalveolar lavage (BAL) revealed Exophiala der-
matidis. The patient commenced on voriconazole but
unfortunately developed long QT-syndrome. Exophiala
growth persisted with evidence of voriconazole resist-
ance. Chest CT showed extensive bronchiectasis and air
trapping. There was no sign of allergic sensitisation to
fungus and the patient had normal immune function.
The discussion focussed on dual -azole therapy, drug
monitoring and inhaled antifungal treatments.
Marco Poeta (Italy) presented four cases of persistent
wet cough with diverse diagnoses highlighting the im-
portance of differential diagnosis and comprehensive in-
vestigation. The first two children were diagnosed with
congenital vascular anomalies. One patient underwent
aortopexy with resolution of her symptoms. The third
case was diagnosed with type 2 congenital pulmonary
airway malformation and symptoms resolved following
lobectomy. The fourth case was a 7-year-old with recur-
rent lower respiratory tract infections, decreased lung
function and Pseudomonas aeruginosa in her sputum.
PCD diagnostics showed nNO 7 ppb, ODA defect on
TEM and genetics are awaited.
Anne Schmidt (UK) presented the case of a 19-year-
old woman with bronchiectasis, hydrocephalus and bilat-
eral hydrosalpinx. She presented at 6 weeks old with
aqueduct stenosis and hydrocephalus requiring insertion
of a ventriculoperitoneal shunt. She underwent diagnos-
tic work-up including PCD diagnostics at age 6 and 14
years. Results showed normal nNO and TEM but a low
ciliary beat frequency (CBF) and a stiff dyskinetic beat
pattern increasing the suspicion of a ciliopathy. At 15
years, she developed a significant drop in lung function
(FEV1 80 to 54%) with Aspergillus fumigatus infection
on BAL. She was managed with intravenous antifungals
but continues to have recurrent chest infections caused
by other bacterial organisms. This case stimulated dis-
cussion on whether this represented fungal bronchitis
and various treatment strategies were shared by clini-
cians with similar patients.
Early stage researchers networking forum
The BEAT-PCD Training School hosted the 2nd Early
Stage Researchers (ESR) networking forum led by ESR
representatives Bruna Rubbo (UK) and Myrofora
Goutaki (Switzerland). The networking forum brought
together 39 delegates, including postgraduate students,
clinicians and postdoctoral researchers. Feedback from
the inaugural ESR forum held in the previous Confer-
ence [19] requested the formation of small break-out
groups to discuss hot topics in PCD research. Partici-
pants proposed various subjects, from animal models
to developing a grant proposal. Each break-out group
discussed their topic and elected a speaker to sum-
marise the important points to the larger collective.
Contact details were exchanged amongst participants
with a plan to share ideas and expertise on future
collaborative projects.
Evaluation feedback from participants
An online feedback survey was circulated to the 143 del-
egates following the Conference and Training School.
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Eighty-eight respondents (62% response rate) from 25
countries completed the survey (Fig. 2) with an average
rating of 9.1/10 for the conference and 8/10 for
workshops.
Summary
BEAT-PCD can be characterised as a successful COST-
ACTION, not only through the successful completion
and publication of multiple studies which have advanced
our understanding of PCD, but also through its contri-
bution towards the training of young researchers, facili-
tation of efficient networking which has led to the
development of collaborative projects and the dissemin-
ation of expertise across the world. Moreover, almost all
the participants of BEAT-PCD were involved in multiple
projects, from STSMs to manuscript preparation. This
indicates how interactive the COST-action has been and
the genuine enthusiasm and excitement it has invoked
amongst its participants, as also shown by the high re-
sponse numbers and positive comments received
through the end of meeting feedback survey and the up-
take for participation in the future PreMedCilia COST
application. BEAT-PCD has built upon the previous
work undertaken by BEST-CILIA and has set-up a high
profile and important platform for an exciting, product-
ive and necessary continuation through follow-on fund-
ing streams.
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